Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

(2015)   Oncotarget

Abstract OT2-3-02: Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase Ib preliminary data.

(2014) JL Canon et al.   CANCER RESEARCH

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy

(2013) Seth A. Wander et al.   BREAST CANCER RESEARCH AND TREATMENT

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

(2013) Howard A. Burris   CANCER CHEMOTHERAPY AND PHARMACOLOGY

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

(2013) Carolyn D. Britten   CANCER CHEMOTHERAPY AND PHARMACOLOGY

PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

(2013) A. Herzog et al.   CLINICAL CANCER RESEARCH

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice

(2012) Brett H. Simmons et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

(2012) Naifa L. Busaidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Abstract A167: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology.

(2012) R. Millham et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

(2011) R. Mallon et al.   CLINICAL CANCER RESEARCH

In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer

(2011) K. M. Kinross et al.   MOLECULAR CANCER THERAPEUTICS

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

(2011) J. Yuan et al.   MOLECULAR CANCER THERAPEUTICS

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs

(2011) Shin Ogita et al.   Targeted Oncology

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

(2009) N. T. Ihle et al.   MOLECULAR CANCER THERAPEUTICS

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Mammalian target of rapamycin as a therapeutic target in oncology

(2008) Robert T Abraham et al.   EXPERT OPINION ON THERAPEUTIC TARGETS